Metastatic Liver Cancer- Pipeline Insight, 2024

Metastatic Liver Cancer- Pipeline Insight, 2024

DelveInsight’s, “Metastatic-Liver-Cancer- Pipeline Insight, 2024” report provides comprehensive insights about 20+ companies and 25+ pipeline drugs in Metastatic-Liver-Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Metastatic-Liver-Cancer: Understanding

Metastatic-Liver-Cancer: Overview

The liver is a common site for metastases from many cancer types. Cancers that spread to the liver most often are colorectal cancer as well as with breast, esophageal, stomach, pancreatic, lung, kidney and melanoma skin cancers. Cancers spread to the liver because the liver filters most of the blood from the rest of the body, and when cancer cells break away from a primary cancer, they often enter and travel through the bloodstream. Sometimes the discovery of metastatic liver cancer is the first indication that a person has cancer. Often, the first symptoms are vague. They include weight loss, poor appetite, and sometimes fever. Typically, the liver is enlarged and hard. It may feel tender and often lumpy. Occasionally, the spleen is enlarged. At first, unless the cancer is blocking the bile ducts, the person has mild or no jaundice (a yellowish discoloration of the skin and the whites of the eyes). Later, the abdomen may become swollen (distended) with fluid (a condition called ascites). In the weeks before death, jaundice progressively worsens. People may become confused and drowsy as toxins accumulate in the brain because the liver is too damaged to remove them from the blood. This condition is called hepatic encephalopathy. Doctors may suspect metastatic liver cancer in people who lose weight and have an enlarged liver or who have a cancer that tends to spread to the liver. However, doctors often have difficulty diagnosing the cancer until it is advanced. If doctors suspect liver cancer, liver tests, which are simple blood tests, are done to evaluate how well the liver is functioning. Results may be abnormal, as they are in many disorders. Thus, this finding cannot confirm the diagnosis. Ultrasonography is usually helpful, but computed tomography (CT) and magnetic resonance imaging (MRI) of the liver are usually more accurate in detecting the cancer. Treatment depends on how far the cancer has spread and what the primary cancer is. Options include the following: Chemotherapy drugs, radiation therapy to the liver or Surgery.

""Metastatic-Liver-Cancer- Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Metastatic-Liver-Cancer pipeline landscape is provided which includes the disease overview and Metastatic-Liver-Cancer treatment guidelines. The assessment part of the report embraces, in depth Metastatic-Liver-Cancer commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Metastatic-Liver-Cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Metastatic-Liver-Cancer R&D. The therapies under development are focused on novel approaches to treat/improve Metastatic-Liver-Cancer.

Metastatic-Liver-Cancer Emerging Drugs Chapters

This segment of the Metastatic-Liver-Cancer report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Metastatic-Liver-Cancer Emerging Drugs

• exoASO STAT6: Codiak BioSciences

exoASO™-STAT6 is an exosome therapeutic candidate engineered using our engEx™ Platform to overexpress Codiak’s novel protein scaffold, PTGFRN, to selectively target uptake in M2 polarized tumor-associated macrophages. Currently the drug is in Phase I stage of Clinical trial evaluation for the treatment of Metastatic-Liver-Cancer.

• STP 705: Sirnaomics

STP705, is a dual TGF-ß1/COX-2 inhibitor. TGF-ß1 and COX-2 are well-validated gatekeeper targets for oncology and fibrosis disease drug development. STP705 leverages our locally administered PNP formulation for direct administration to diseased tissue. STP705 has received U.S. orphan drug designation for the treatment of certain hepatocellular carcinomas and liver fibrosis, including: primary sclerosing cholangitis (PSC), cholangiocarcinoma (CCA) and hepatocellular carcinoma (HCC). Currently the drug is in Phase I stage of Clinical trial evaluation for the treatment of Metastatic-Liver-Cancer.

• ONCR 177: Oncorus

ONCR-177, our lead product candidate, is an intratumorally administered Herpes Simplex Virus (HSV) viral immunotherapy for the treatment of multiple solid tumor cancers. ONCR-177 fights tumors through multiple mechanisms, including inherent oncolytic activity, immune stimulation elicited by viral infection and the expression of five transgenes (IL-12, CCL4, FLT3LG, anti-PD-1 and anti-CTLA-4). Currently the drug is in Phase I stage of Clinical trial evaluation for the treatment of Metastatic-Liver-Cancer.

Further product details are provided in the report……..

Metastatic-Liver-Cancer: Therapeutic Assessment

This segment of the report provides insights about the different Metastatic-Liver-Cancer drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Metastatic-Liver-Cancer

There are approx. 20+ key companies which are developing the therapies for Metastatic-Liver-Cancer. The companies which have their Metastatic-Liver-Cancer drug candidates in the most advanced stage, i.e. phase I include, Oncorus.

• Phases

DelveInsight’s report covers around 25+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Metastatic-Liver-Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal
• Molecule Type

Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Metastatic-Liver-Cancer: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Metastatic-Liver-Cancer therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Metastatic-Liver-Cancer drugs.

Metastatic-Liver-Cancer Report Insights

• Metastatic-Liver-Cancer Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Metastatic-Liver-Cancer Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Metastatic-Liver-Cancer drugs?
• How many Metastatic-Liver-Cancer drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Metastatic-Liver-Cancer?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Metastatic-Liver-Cancer therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Metastatic-Liver-Cancer and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Oncorus
• Sirnaomics
• Codiak BioSciences
• Sorrento Therapeutics, Inc.
• RemeGen Co., Ltd.
• Taiho Pharmaceutical Co., Ltd.
• Amarin Corporation
• Eureka Therapeutics
• Medivir AB
• AstraZeneca
• Amal Therapeutics
• Boehringer Ingelheim

Key Products

• exoASO STAT6
• STP 705
• ONCR 177
• anti-CEA CAR-T cells
• RC48-ADC
• DNX-2440
• Tas-102
• Ethyl eicosapentaenoic acid
• ECT 204
• ET140203
• MIV-818
• Durvalumab
• STI-1386
• ATP128